Global Hepatitis A and B Vaccination 麻豆原创 Growth 2025-2031

Publication ID:

LPI03257393

Publication Date:

March 4, 2025

Pages:

119

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Hepatitis A and B Vaccination market size is predicted to grow from US$ 1849 million in 2025 to US$ 2066 million in 2031; it is expected to grow at a CAGR of 1.9% from 2025 to 2031.
The hepatitis A and hepatitis B vaccines听can be given separately or as a combination vaccine. All the shots in the series are needed for long-term protection. The full series of the hepatitis A and hepatitis B vaccines require 2-3 shots, depending on the type of vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淗epatitis A and B Vaccination Industry Forecast鈥� looks at past sales and reviews total world Hepatitis A and B Vaccination sales in 2024, providing a comprehensive analysis by region and market sector of projected Hepatitis A and B Vaccination sales for 2025 through 2031. With Hepatitis A and B Vaccination sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatitis A and B Vaccination industry.
This Insight Report provides a comprehensive analysis of the global Hepatitis A and B Vaccination landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatitis A and B Vaccination portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Hepatitis A and B Vaccination market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis A and B Vaccination and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis A and B Vaccination.
This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis A and B Vaccination market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Hepatitis A Vaccination
Hepatitis B Vaccination
Segmentation by Application:
Government Institution
Private Sector
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GSK
Merck
Sanofi
Sinovac
Zhejiang Pukang
Changchun Institute of Biological
KM Biologics
IMBCAMS
Convac
NCPC
Bio Kangtai
Dynavax
Hissen
LG Life Sciences
Serum Institute
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hepatitis A and B Vaccination market?
What factors are driving Hepatitis A and B Vaccination market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hepatitis A and B Vaccination market opportunities vary by end market size?
How does Hepatitis A and B Vaccination break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Hepatitis A and B Vaccination Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Hepatitis A and B Vaccination by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Hepatitis A and B Vaccination by Country/Region, 2020, 2024 & 2031
2.2 Hepatitis A and B Vaccination Segment by Type
2.2.1 Hepatitis A Vaccination
2.2.2 Hepatitis B Vaccination
2.3 Hepatitis A and B Vaccination Sales by Type
2.3.1 Global Hepatitis A and B Vaccination Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Hepatitis A and B Vaccination Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Hepatitis A and B Vaccination Sale Price by Type (2020-2025)
2.4 Hepatitis A and B Vaccination Segment by Application
2.4.1 Government Institution
2.4.2 Private Sector
2.4.3 Other
2.5 Hepatitis A and B Vaccination Sales by Application
2.5.1 Global Hepatitis A and B Vaccination Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Hepatitis A and B Vaccination Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Hepatitis A and B Vaccination Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Hepatitis A and B Vaccination Breakdown Data by Company
3.1.1 Global Hepatitis A and B Vaccination Annual Sales by Company (2020-2025)
3.1.2 Global Hepatitis A and B Vaccination Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Hepatitis A and B Vaccination Annual Revenue by Company (2020-2025)
3.2.1 Global Hepatitis A and B Vaccination Revenue by Company (2020-2025)
3.2.2 Global Hepatitis A and B Vaccination Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Hepatitis A and B Vaccination Sale Price by Company
3.4 Key Manufacturers Hepatitis A and B Vaccination Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hepatitis A and B Vaccination Product Location Distribution
3.4.2 Players Hepatitis A and B Vaccination Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Hepatitis A and B Vaccination by Geographic Region
4.1 World Historic Hepatitis A and B Vaccination 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Hepatitis A and B Vaccination Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Hepatitis A and B Vaccination Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Hepatitis A and B Vaccination 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Hepatitis A and B Vaccination Annual Sales by Country/Region (2020-2025)
4.2.2 Global Hepatitis A and B Vaccination Annual Revenue by Country/Region (2020-2025)
4.3 Americas Hepatitis A and B Vaccination Sales Growth
4.4 APAC Hepatitis A and B Vaccination Sales Growth
4.5 Europe Hepatitis A and B Vaccination Sales Growth
4.6 Middle East & Africa Hepatitis A and B Vaccination Sales Growth
5 Americas
5.1 Americas Hepatitis A and B Vaccination Sales by Country
5.1.1 Americas Hepatitis A and B Vaccination Sales by Country (2020-2025)
5.1.2 Americas Hepatitis A and B Vaccination Revenue by Country (2020-2025)
5.2 Americas Hepatitis A and B Vaccination Sales by Type (2020-2025)
5.3 Americas Hepatitis A and B Vaccination Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hepatitis A and B Vaccination Sales by Region
6.1.1 APAC Hepatitis A and B Vaccination Sales by Region (2020-2025)
6.1.2 APAC Hepatitis A and B Vaccination Revenue by Region (2020-2025)
6.2 APAC Hepatitis A and B Vaccination Sales by Type (2020-2025)
6.3 APAC Hepatitis A and B Vaccination Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hepatitis A and B Vaccination by Country
7.1.1 Europe Hepatitis A and B Vaccination Sales by Country (2020-2025)
7.1.2 Europe Hepatitis A and B Vaccination Revenue by Country (2020-2025)
7.2 Europe Hepatitis A and B Vaccination Sales by Type (2020-2025)
7.3 Europe Hepatitis A and B Vaccination Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hepatitis A and B Vaccination by Country
8.1.1 Middle East & Africa Hepatitis A and B Vaccination Sales by Country (2020-2025)
8.1.2 Middle East & Africa Hepatitis A and B Vaccination Revenue by Country (2020-2025)
8.2 Middle East & Africa Hepatitis A and B Vaccination Sales by Type (2020-2025)
8.3 Middle East & Africa Hepatitis A and B Vaccination Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hepatitis A and B Vaccination
10.3 Manufacturing Process Analysis of Hepatitis A and B Vaccination
10.4 Industry Chain Structure of Hepatitis A and B Vaccination
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hepatitis A and B Vaccination Distributors
11.3 Hepatitis A and B Vaccination Customer
12 World Forecast Review for Hepatitis A and B Vaccination by Geographic Region
12.1 Global Hepatitis A and B Vaccination 麻豆原创 Size Forecast by Region
12.1.1 Global Hepatitis A and B Vaccination Forecast by Region (2026-2031)
12.1.2 Global Hepatitis A and B Vaccination Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Hepatitis A and B Vaccination Forecast by Type (2026-2031)
12.7 Global Hepatitis A and B Vaccination Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Hepatitis A and B Vaccination Product Portfolios and Specifications
13.1.3 GSK Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Hepatitis A and B Vaccination Product Portfolios and Specifications
13.2.3 Merck Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Hepatitis A and B Vaccination Product Portfolios and Specifications
13.3.3 Sanofi Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Sinovac
13.4.1 Sinovac Company Information
13.4.2 Sinovac Hepatitis A and B Vaccination Product Portfolios and Specifications
13.4.3 Sinovac Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sinovac Main Business Overview
13.4.5 Sinovac Latest Developments
13.5 Zhejiang Pukang
13.5.1 Zhejiang Pukang Company Information
13.5.2 Zhejiang Pukang Hepatitis A and B Vaccination Product Portfolios and Specifications
13.5.3 Zhejiang Pukang Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Zhejiang Pukang Main Business Overview
13.5.5 Zhejiang Pukang Latest Developments
13.6 Changchun Institute of Biological
13.6.1 Changchun Institute of Biological Company Information
13.6.2 Changchun Institute of Biological Hepatitis A and B Vaccination Product Portfolios and Specifications
13.6.3 Changchun Institute of Biological Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Changchun Institute of Biological Main Business Overview
13.6.5 Changchun Institute of Biological Latest Developments
13.7 KM Biologics
13.7.1 KM Biologics Company Information
13.7.2 KM Biologics Hepatitis A and B Vaccination Product Portfolios and Specifications
13.7.3 KM Biologics Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 KM Biologics Main Business Overview
13.7.5 KM Biologics Latest Developments
13.8 IMBCAMS
13.8.1 IMBCAMS Company Information
13.8.2 IMBCAMS Hepatitis A and B Vaccination Product Portfolios and Specifications
13.8.3 IMBCAMS Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 IMBCAMS Main Business Overview
13.8.5 IMBCAMS Latest Developments
13.9 Convac
13.9.1 Convac Company Information
13.9.2 Convac Hepatitis A and B Vaccination Product Portfolios and Specifications
13.9.3 Convac Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Convac Main Business Overview
13.9.5 Convac Latest Developments
13.10 NCPC
13.10.1 NCPC Company Information
13.10.2 NCPC Hepatitis A and B Vaccination Product Portfolios and Specifications
13.10.3 NCPC Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 NCPC Main Business Overview
13.10.5 NCPC Latest Developments
13.11 Bio Kangtai
13.11.1 Bio Kangtai Company Information
13.11.2 Bio Kangtai Hepatitis A and B Vaccination Product Portfolios and Specifications
13.11.3 Bio Kangtai Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Bio Kangtai Main Business Overview
13.11.5 Bio Kangtai Latest Developments
13.12 Dynavax
13.12.1 Dynavax Company Information
13.12.2 Dynavax Hepatitis A and B Vaccination Product Portfolios and Specifications
13.12.3 Dynavax Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Dynavax Main Business Overview
13.12.5 Dynavax Latest Developments
13.13 Hissen
13.13.1 Hissen Company Information
13.13.2 Hissen Hepatitis A and B Vaccination Product Portfolios and Specifications
13.13.3 Hissen Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Hissen Main Business Overview
13.13.5 Hissen Latest Developments
13.14 LG Life Sciences
13.14.1 LG Life Sciences Company Information
13.14.2 LG Life Sciences Hepatitis A and B Vaccination Product Portfolios and Specifications
13.14.3 LG Life Sciences Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 LG Life Sciences Main Business Overview
13.14.5 LG Life Sciences Latest Developments
13.15 Serum Institute
13.15.1 Serum Institute Company Information
13.15.2 Serum Institute Hepatitis A and B Vaccination Product Portfolios and Specifications
13.15.3 Serum Institute Hepatitis A and B Vaccination Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Serum Institute Main Business Overview
13.15.5 Serum Institute Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.